- Home
- ACIC vs PLRX Comparison
ACIC vs PLRX Comparison
Compare ACIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.23
Company Overview
Basic Information| Metric | ACIC | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.7M | 93.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PLRX |
|---|---|---|
| Price | $12.67 | $1.23 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $3.79 |
| AVG Volume (30 Days) | 121.7K | ★ 1.8M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $328,331,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.40 | N/A |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | ★ 22.22 | N/A |
| 52 Week Low | $9.97 | $1.10 |
| 52 Week High | $14.25 | $15.00 |
Technical Indicators
Market Signals| Indicator | ACIC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 65.80 | 34.01 |
| Support Level | $11.91 | $1.17 |
| Resistance Level | $12.30 | $1.35 |
| Average True Range (ATR) | 0.26 | 0.12 |
| MACD | 0.08 | -0.03 |
| Stochastic Oscillator | 100.00 | 15.38 |
Price Performance
Historical Comparison ACIC
PLRX
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.